Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

MRNS

Marinus Pharmaceuticals Inc

Dec 13 • 04:00PM ET

0.2628

Dollar change -0.0094
Percentage change -3.45	%

Healthcare • Biotechnology • USA • NASD

Peers: AXSM NBIX ACAD SAGE CYTK SUPN XENE AVDL PTCT VTGN

| Held by: VTI VXF IBB IWC ITOT BTEC BIB IBBQ

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.47	Insider Own	24.13%	Shs Outstand	55.19M	Perf Week	-8.75%
Market Cap	14.00M	Forward P/E	-	EPS next Y	-0.64	Insider Trans	-0.23%	Shs Float	41.87M	Perf Month	-13.07%
Income	-140.49M	PEG	-	EPS next Q	-0.30	Inst Own	62.83%	Short Float	10.46%	Perf Quarter	-83.05%
Sales	31.47M	P/S	0.44	EPS this Y	22.86%	Inst Trans	-16.13%	Short Ratio	1.69	Perf Half Y	-82.06%
Book/sh	-1.21	P/B	-	EPS next Y	68.46%	ROA	-106.26%	Short Interest	4.38M	Perf Year	-97.02%
Cash/sh	0.79	P/C	0.33	EPS next 5Y	-	ROE	-2986.55%	52W Range	0.26 - 11.26	Perf YTD	-97.58%
Dividend Est.	-	P/FCF	-	EPS past 5Y	6.04%	ROI	-1275.80%	52W High	-97.67%	Beta	1.20
Dividend TTM	-	Quick Ratio	1.47	Sales past 5Y	176.17%	Gross Margin	88.49%	52W Low	0.96%	ATR (14)	0.04
Dividend Ex-Date	-	Current Ratio	1.66	EPS Y/Y TTM	6.97%	Oper. Margin	-389.70%	RSI (14)	27.53	Volatility	7.82% 7.52%
Employees	165	Debt/Eq	-	Sales Y/Y TTM	1.63%	Profit Margin	-446.49%	Recom	2.56	Target Price	1.47
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	30.78%	Payout	-	Rel Volume	0.35	Prev Close	0.27
Sales Surprise	-9.35%	EPS Surprise	-2.64%	Sales Q/Q	16.39%	Earnings	Nov 12 AMC	Avg Volume	2.60M	Price	0.26
SMA20	-13.45%	SMA50	-63.53%	SMA200	-88.81%	Trades		Volume	920,950	Change	-3.45%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-23-24	Upgrade	Oppenheimer	Perform → Outperform	$6
Aug-14-24	Downgrade	Ladenburg Thalmann	Buy → Neutral
Apr-16-24	Downgrade	Robert W. Baird	Outperform → Neutral	$20 → $2
Apr-15-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$24 → $3
Aug-11-23	Downgrade	Oppenheimer	Outperform → Perform	$14 → $9
Jan-20-23	Initiated	RBC Capital Mkts	Outperform	$23
Sep-30-20	Initiated	Truist	Buy	$35
Jul-01-20	Reiterated	H.C. Wainwright	Buy	$6 → $9
Jul-01-20	Initiated	Cowen	Outperform
Apr-09-20	Initiated	Craig Hallum	Buy	$4.50
Dec-20-19	Initiated	Oppenheimer	Outperform
Mar-05-19	Resumed	Jefferies	Buy	$3.50 → $10
Feb-27-19	Downgrade	Mizuho	Buy → Neutral	$13 → $5
Feb-06-19	Initiated	Leerink Partners	Outperform	$10
Jul-02-18	Initiated	Cantor Fitzgerald	Overweight	$19
Mar-20-18	Initiated	Mizuho	Buy	$13
Feb-15-18	Initiated	H.C. Wainwright	Buy	$33
Dec-14-17	Initiated	Laidlaw	Buy	$18
Aug-10-16	Reiterated	Jefferies	Buy	$2.50 → $3
Jun-14-16	Downgrade	RBC Capital Mkts	Outperform → Sector Perform

Show Previous Ratings

Nov-12-24 05:10PM	Marinus Pharmaceuticals (MRNS) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -12.35%
04:04PM	Marinus Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
04:00PM	Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results (Business Wire)
Oct-25-24 07:28AM	Marinus clinical trial of ganaxolone fails to meet primary endpoint (Clinical Trials Arena) +36.86%
06:35AM	GSK invests $800M in manufacturing; Amgen sets small discount for Eylea biosimilar (BioPharma Dive)
12:42PM	Loading…
Oct-24-24 12:42PM	Marinus Pharmaceuticals' Oral Seizure Drug Disappoints In Late-Stage Study, Appoints Advisor To Explore Options (Benzinga) -82.49%
08:00AM	Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives (Business Wire)
Oct-18-24 11:17AM	Marinus reports Phase III RAISE trial results for ganaxolone in RSE treatment (Clinical Trials Arena) +6.32%
Oct-17-24 07:00AM	Marinus Pharmaceuticals Presents Clinical Data From Pivotal Phase 3 RAISE Trial in Refractory Status Epilepticus at the Neurocritical Care Society 2024 Annual Meeting (Business Wire)
Oct-15-24 04:57PM	Health Care Roundup: Market Talk (The Wall Street Journal)
04:00PM	Marinus Pharmaceuticals Further Strengthens Intellectual Property Estate with Method of Treatment Patent for ZTALMY Titration Regimens (Business Wire)
Oct-09-24 07:00AM	Marinus Pharmaceuticals Announces Podium and Poster Presentations at the Neurocritical Care Society 2024 Annual Meeting (Business Wire)
Oct-08-24 04:04PM	Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire) -5.95%
Oct-03-24 10:14AM	Heres Why PGIM Jennison Health Sciences Fund Reduced its Position in Marinus Pharmaceuticals (MRNS) (Insider Monkey)
Sep-20-24 08:00AM	Marinus Pharmaceuticals to Highlight Clinical Progress and Commercial Launch Preparedness for ZTALMY in TSC at Investor and Analyst Day (Business Wire)
08:00AM	Loading…
Sep-12-24 08:00AM	Marinus Pharmaceuticals Announces Agenda and Speakers for Investor & Analyst Day on September 20, 2024 (Business Wire)
Sep-10-24 08:00AM	Marinus Pharmaceuticals to Present at the 2024 Cantor Global Healthcare Conference (Business Wire)
Aug-19-24 08:00AM	Marinus Pharmaceuticals to Host Investor and Analyst Day on Friday, September 20, 2024 (Business Wire) +5.56%
Aug-14-24 03:39AM	Q2 2024 Marinus Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -6.78%
Aug-13-24 08:10AM	Marinus Pharmaceuticals (MRNS) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:07AM	Marinus Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results (Business Wire)
Aug-06-24 08:00AM	3 Biotech Stocks to Sell in August Before They Crash & Burn (InvestorPlace)
Jul-30-24 08:00AM	Marinus Pharmaceuticals to Provide Business Update and Report Second Quarter 2024 Financial Results on August 13, 2024 (Business Wire)
Jul-24-24 11:28PM	Marinus Pharmaceuticals, Inc. (MRNS): A Good One-Dollar Stock According to Street Analysts? (Insider Monkey)
Jul-22-24 05:45AM	Shareholders of Marinus Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before August 5, 2024 to Discuss Your Rights - MRNS (PR Newswire)
Jul-18-24 07:00AM	Marinus Pharmaceuticals Announces Ganaxolone Approved in China as First Treatment for Seizures Associated with CDKL5 Deficiency Disorder (Business Wire)
05:45AM	Shareholders of Marinus Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before August 5, 2024 to Discuss Your Rights - MRNS (PR Newswire)
Jul-15-24 10:45AM	Ovid Therapeutics Inc. (OVID): One of the Best Penny Stocks to Buy Under $1 According to Hedge Funds? (Insider Monkey)
09:35AM	10 Best Penny Stocks to Buy Under $1 (Insider Monkey)
04:52AM	Loading…
Jun-18-24 04:52AM	Marinus Pharmaceuticals reports data from refractory status epilepticus drug trial (Clinical Trials Arena)
Jun-17-24 07:00AM	Marinus Pharmaceuticals Announces Topline Results from Phase 3 RAISE Trial of IV Ganaxolone in Refractory Status Epilepticus (Business Wire)
May-17-24 10:44AM	Marinus Completes Enrollment in Tuberous Sclerosis Complex Trial; Gets New Patent (MT Newswires)
09:35AM	Here's Why Marinus Pharmaceuticals (MRNS) is Poised for a Turnaround After Losing -7.8% in 4 Weeks (Zacks)
07:00AM	Marinus Pharmaceuticals Announces Key Business Updates for Tuberous Sclerosis Complex Program (Business Wire)
May-16-24 09:35AM	After Plunging -7.64% in 4 Weeks, Here's Why the Trend Might Reverse for Marinus Pharmaceuticals (MRNS) (Zacks)
May-08-24 01:22PM	Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2024 Earnings Call Transcript (Insider Monkey) -8.92%
11:54AM	MRNS Stock Earnings: Marinus Pharma Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:30AM	Marinus Pharmaceuticals (MRNS) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:29AM	Marinus Pharmaceuticals: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results (Business Wire)
May-07-24 10:18AM	HC Wainwright Adjusts Price Target on Marinus Pharmaceuticals to $11 From $27, Maintains Buy Rating (MT Newswires) +6.08%
May-02-24 08:00AM	Marinus Pharmaceuticals to Present at the RBC Capital Markets 2024 Global Healthcare Conference (Business Wire)
May-01-24 08:00AM	Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2024 Financial Results on May 8, 2024 (Business Wire)
Apr-16-24 11:46AM	Marinus (MRNS) Down 83% on Lead Drug Falling Short in Seizure Study (Zacks) -7.69%
Apr-15-24 12:54PM	Biotech on a Budget: 7 Stocks Under $10 With Huge Potential (InvestorPlace) -82.71%
11:30AM	Why Is Marinus Pharmaceuticals (MRNS) Stock Down 79% Today? (InvestorPlace)
07:00AM	Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results (Business Wire)
Apr-05-24 04:00PM	Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire) -10.14% +5.13%
Mar-27-24 08:41AM	Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus' Post Grant Review (Business Wire)
Mar-25-24 10:00AM	DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-20-24 10:32AM	Do Options Traders Know Something About Marinus (MRNS) Stock We Don't? (Zacks)
Mar-07-24 01:41PM	Marinus Pharmaceuticals Inc (MRNS) Reports Full Year and Q4 2023 Financial Results (GuruFocus.com)
11:10AM	Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-06-24 07:14AM	Q4 2023 Marinus Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-05-24 05:10PM	Marinus Pharmaceuticals (MRNS) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:24PM	Marinus Pharmaceuticals: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
Feb-21-24 07:00AM	Marinus Pharmaceuticals to Present at Upcoming Investor Conferences (Business Wire)
Feb-20-24 07:00AM	Marinus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024 (Business Wire)
Feb-16-24 04:00PM	Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
Jan-30-24 08:13PM	Marinus Pharmaceuticals Stock (NASDAQ:MRNS): This Drugmaker Boasts a Rare Treatment (TipRanks)
Jan-22-24 09:56AM	Should You Add Marinus (MRNS) Stock to Your Portfolio Now? (Zacks) +5.31%
Jan-17-24 09:55AM	Wall Street Analysts Think Marinus Pharmaceuticals (MRNS) Could Surge 113.01%: Read This Before Placing a Bet (Zacks)
Jan-04-24 04:30PM	Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
07:01AM	Marinus Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2023 ZTALMY Net Product Revenue and Provides Business Update (Business Wire)
Dec-29-23 06:45AM	5 Most Promising Long-Term Stocks According to Analysts (Insider Monkey)
Dec-07-23 04:30PM	Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
Nov-20-23 04:01PM	Marinus Pharmaceuticals Announces Seven Presentations at AES 2023, New Publication in Epilepsia and Results From the Second Generation Formulation MAD Study (Business Wire)
Nov-14-23 04:05PM	Marinus Pharmaceuticals to Present at the 6th Annual Evercore ISI HealthCONx Conference (Business Wire) -5.45%
Nov-09-23 04:30PM	Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire) -14.07%
Nov-08-23 04:32PM	Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Q3 2023 Earnings Call Transcript (Insider Monkey) +5.91%
Nov-07-23 07:55AM	Marinus Pharmaceuticals Inc (MRNS) Reports Q3 2023 Financial Results (GuruFocus.com)
07:36AM	Marinus Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
07:01AM	Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results (Business Wire)
07:00AM	Marinus Pharmaceuticals Initiates Global Access Program for ZTALMY (ganaxolone) Oral Suspension CV (Business Wire)
Oct-24-23 07:01AM	Marinus Pharmaceuticals to Provide Business Update and Report Third Quarter 2023 Financial Results on November 7, 2023 (Business Wire)
Oct-11-23 09:55AM	Wall Street Analysts Believe Marinus Pharmaceuticals (MRNS) Could Rally 183.33%: Here's is How to Trade (Zacks)
Oct-06-23 04:00PM	Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire) -5.43%
Sep-21-23 04:00PM	Marinus Pharmaceuticals to Present at the 2023 Cantor Global Healthcare Conference (Business Wire) -6.18%
Sep-20-23 09:02AM	Marinus Pharmaceuticals (MRNS) Soars 19.9%: Is Further Upside Left in the Stock? (Zacks)
09:01AM	Marinus (MRNS) Up 20% on Financial and Pipeline Updates (Zacks)
Sep-19-23 04:51PM	Marinus Pharmaceuticals extends cash runway, shares surge 16% (Investing.com) +19.88%
08:00AM	Marinus Pharmaceuticals Highlights Advancing Pipeline and Commercial Strategy at Investor and Analyst Event (Business Wire)
Sep-12-23 04:00PM	Marinus Pharmaceuticals Announces Speakers for Hybrid Investor & Analyst Event on Tuesday, September 19, 2023 (Business Wire) -5.16%
Sep-06-23 04:01PM	Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire) -8.46%
Aug-17-23 04:01PM	Marinus Pharmaceuticals to Host Hybrid Investor & Analyst Event on Tuesday, September 19, 2023 (Business Wire) +7.63%
Aug-11-23 04:01PM	Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire) -13.56%
09:36AM	Twilio upgraded, Sealed Air downgraded: Wall Street's top analyst calls (The Fly)
Aug-10-23 08:40AM	Marinus Pharmaceuticals (MRNS) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -9.10%
07:34AM	Marinus Pharmaceuticals: Q2 Earnings Snapshot (AP Finance)
07:01AM	Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results (Business Wire)
Jul-31-23 12:03PM	Marinus secures European Commission approval for Ztalmy (American City Business Journals) +5.03%
07:01AM	Marinus Pharmaceuticals Announces European Commission Approval of ZTALMY® (ganaxolone) for the Adjunctive Treatment of Epileptic Seizures Associated with CDKL5 Deficiency Disorder (Business Wire)
Jul-27-23 07:01AM	Marinus Pharmaceuticals to Provide Business Update and Report Second Quarter 2023 Financial Results on August 10, 2023 (Business Wire)
Jul-25-23 03:48PM	Marinus Pharmaceuticals (NASDAQ:MRNS) shareholders have earned a 71% return over the last year (Simply Wall St.)
Jul-13-23 04:30PM	Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
Jul-03-23 04:23AM	Strength Seen in Marinus Pharmaceuticals (MRNS): Can Its 5.4% Jump Turn into More Strength? (Zacks)
Jun-21-23 04:01PM	Marinus Pharmaceuticals Announces New Method of Use Patent Granted for IV Ganaxolone by USPTO in Status Epilepticus (Business Wire)
Jun-12-23 07:59AM	Institutional investors are Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) biggest bettors and were rewarded after last week's US$149m market cap gain (Simply Wall St.)

Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded in August 2003 and is headquartered in Radnor, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Saraswathy Nochur	Director	Dec 10 '24	Proposed Sale	0.28	13,250	3,743		Dec 10 03:18 PM
Pfanstiel Steven	CFO AND COO	Aug 05 '24	Sale	1.13	4,657	5,262	79,773	Aug 07 04:05 PM
Shafer Christina	CHIEF COMMERCIAL OFFICER	Aug 05 '24	Sale	1.14	3,820	4,355	67,406	Aug 07 04:05 PM
MANNING MARTHA E	SVP, GEN. COUNSEL & CORP. SEC.	Aug 05 '24	Sale	1.13	3,621	4,092	60,263	Aug 07 04:05 PM
Hulihan Joseph	CHIEF MEDICAL OFFICER	Aug 05 '24	Sale	1.13	4,828	5,456	72,725	Aug 07 04:05 PM
Braunstein Scott	CHAIRMAN AND CEO	Aug 05 '24	Sale	1.13	12,145	13,724	298,667	Aug 07 04:05 PM
Braunstein Scott	CHAIRMAN AND CEO	Mar 27 '24	Option Exercise	4.28	50,000	214,000	273,512	Mar 27 11:55 AM
Shafer Christina	CHIEF COMMERCIAL OFFICER	Feb 20 '24	Sale	9.56	2,153	20,583	60,308	Feb 22 04:05 PM
MANNING MARTHA E	SVP, GEN. COUNSEL & CORP. SEC.	Feb 20 '24	Sale	9.57	1,894	18,126	52,966	Feb 22 04:05 PM
Hulihan Joseph	CHIEF MEDICAL OFFICER	Feb 16 '24	Sale	9.98	2,814	28,084	66,635	Feb 21 04:06 PM
Pfanstiel Steven	CFO AND COO	Feb 16 '24	Sale	9.97	3,092	30,827	71,697	Feb 21 04:05 PM
Braunstein Scott	CHAIRMAN AND CEO	Feb 16 '24	Sale	9.94	11,850	117,789	223,512	Feb 21 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MRNS

Marinus Pharmaceuticals Inc

Upgrade your FINVIZ experience